[68ga]ga-dwj155
Gastric/Gastroesophageal Junction (GEJ) Cancer
Novartis PharmaceuticalsradiopharmaceuticalPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
46 Active assets in the Gastric/Gastroesophageal Junction (GEJ) Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Iambic Therapeutics, Inc | Phase 1/2 | B |
Eloxatin Incyte Corporation | Phase 1/2 | B |
FLUOROURACILUM Incyte Corporation | Phase 1/2 | B |
Cyclophosphamide Diwakar Davar | Phase 2 | B |
Pembrolizumab Diwakar Davar | Phase 2 | B |
View all 50 →
Same molecule, other indications
[68ga]ga-dwj155 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →